S-1/A: Invizyne Technologies Inc. Files Amendment No. 3 to Form S-1 for Initial Public Offering

Invizyne Technologies Inc. has filed an amendment to its Form S-1 registration statement for its initial public offering of 4,300,000 shares of common stock at $4.00 per share, while also registering shares for a selling security holder.

Summary

• Invizyne Technologies Inc., a biomanufacturing company, is planning an initial public offering of 4,300,000 shares of its common stock at a price of $4.00 per share.
• The company intends to list its common stock on The Nasdaq Capital Market under the symbol IZTC.
• MDB Capital Holdings, LLC, the majority holder of Invizyne's common stock, is offering 8,027,538 shares of common stock as a selling security holder.
• The company is an emerging growth company and has taken advantage of certain reduced disclosure obligations.
• Net proceeds from the offering are estimated to be approximately $15.3 million, which will be used to expand production capabilities, increase staff, expand business development, sales and marketing efforts, expand research and development, and add to working capital.
• The underwriter, Public Ventures, LLC, is a wholly owned subsidiary of MDB, creating a conflict of interest that is being addressed by Digital Offering LLC acting as a qualified independent underwriter.
• The company has granted the underwriter a 45-day option to purchase up to 645,000 additional shares to cover over-allotments.
• The company has received US government grants, particularly from the Department of Energy (DOE) for work related to isobutanol, upgrading alcohols, and cofactor development, and the National Institutes of Health (NIH), for work relating to cannabinoids.
• To date, the grants have together totaled $12,739,318, since inception.

Sentiment

Score: 6

Explanation: The document is factual and descriptive, outlining the terms of the IPO and related information. The sentiment is neutral, with a mix of potential positives (use of proceeds for growth) and negatives (risks associated with a development stage company).

Positives

• The company has a commercialization strategy to collaborate with third parties to engage in aspects of product research, testing, marketing, manufacturing, and product distribution.
• The company has received US government grants, particularly from the Department of Energy (DOE) for work related to isobutanol, upgrading alcohols, and cofactor development, and the National Institutes of Health (NIH), for work relating to cannabinoids.
• To date, the grants have together totaled $12,739,318, since inception.

Negatives

• Invizyne is a pre-revenue, development stage company with a limited operating history.
• The company anticipates needing additional funding in the future.
• The company is highly dependent on retaining scientific staff and hiring additional staff.
• The company does not have any sales, marketing, manufacturing and distribution capabilities or arrangements.
• The underwriter, Public Ventures, LLC, is a wholly owned subsidiary of MDB, the company's majority shareholder, creating a conflict of interest.

Risks

• The company may not be able to sustain its operations or become profitable.
• The synthetic biological platform being developed may not develop commercial products or be adopted by clients.
• Regulatory hurdles may have to be satisfied before the bio-synthesized compounds can be marketed and commercially used.
• Laboratory conditions may not be reproduced in a commercial setting.
• The company's processes rely on the need for purified enzymes and co-factors, which are energy molecules.
• The company is highly dependent on a small number of products based on its principal technology.
• The inability to enter into collaboration arrangements as needed, or if such collaborations are not successful, may adversely impact the business.
• The company will face extensive competition from legacy processes and other companies seeking to use bio-manufacturing and enzyme pathways.
• The company may be unable to protect the intellectual property used in its technology platform and products.
• The company will incur increased costs as a result of operating as a public company.
• The company is an emerging growth company and a smaller reporting company, which may make its Common Stock less attractive to investors.
• The company's Common Stock may potentially experience rapid and substantial price volatility, and price decline.
• Concentration of ownership among existing executive officers, directors and significant stockholders may prevent new investors from influencing significant corporate decisions.
• The price of the company's Common Stock may have little or no relationship to the historical sales price of its capital stock in private placement transactions.
• The company's failure to meet the continued listing requirements of Nasdaq could result in a delisting of its Common Stock.
• The company may allocate the net proceeds from this offering in ways that differ from the estimates discussed in the section titled Use of Proceeds.
• You will experience immediate dilution in the book value per share of the Common Stock you purchase.
• Because the underwriter, Public Ventures, LLC is a wholly owned subsidiary of MDB, and MDB prior to the offering beneficially owns 62.88% of our Common Stock, there may be a conflict of interest among the Company, underwriter and MDB in conducting the offering and its terms.

Future Outlook

The company intends to use the net proceeds from this offering to expand the production capabilities of the Company, including capital expenditures, to increase our staff, to expand our business development, sales and marketing efforts, to expand our research and development and technology platform and to add to our working capital.

Industry Context

Invizyne is operating in the synthetic biology market, which is focused on developing chemical feedstocks from renewable sources and using catalytic chemistry to create high-value chemicals that replace petrochemical products. The biobased industry is expanding into sectors such as agriculture, food production, cleaning products, and lubricants.

Comparison to Industry Standards

• The document mentions companies like Debut Biotech and Solugen Inc. that promote cell-free enzymatic systems, but their processes appear to use simple one to two step pathways.
• Codexis, Inc. partnered with Tate&Lyle and Merck & Co., Inc. on different, highly specific projects that use multi enzyme pathways, which demonstrate that enzymatic Islatravir synthesis illustrates the potential for complex or longer enzyme cascades of the type used in some of our SimplePath systems, but their principal mission diverges from the enzymatic manufacturing of more general chemicals.
• There are many companies that focus on enzyme engineering, such as Codexis, Inc., Allozymes Pte Ltd. (Singapore), Enzymit Ltd. (Israel and US), Zymtronix Catalytic Systems, Inc., Arzeda Corp. and Quantumzyme LLP (India).
• There are many companies operating in the biofuels space, such as Valero Energy Corporation, ADM Corporation and Cargill Company and Gevo, Inc. and Butamax Advanced Biofuels LLC that focus on ethanol technologies.

Related Party Transactions

• The underwriter, Public Ventures, LLC, is a wholly owned subsidiary of MDB, the company's majority shareholder, creating a conflict of interest that is being addressed by Digital Offering LLC acting as a qualified independent underwriter.
• Messrs. Christopher Marlett, Anthony DiGiandomenico are majority shareholders and directors of MDB, and directors of the Company.
• Mr. Mo Hayat, the Chairman of the Board and President of the Company, also is the Chief of Entrepreneurship & Operations of MDB.

Stakeholder Impact

• New investors will experience immediate dilution in the book value per share of the Common Stock they purchase.
• Existing shareholders may see their ownership diluted by the issuance of new shares.
• The company's ability to execute its business plan and achieve profitability will impact the value of the stock for all shareholders.

Next Steps

• The company intends to list its common stock on The Nasdaq Capital Market under the symbol IZTC.
• The underwriter expects to deliver the shares to purchasers on or about , 2024.

Key Dates

Keywords

initial public offering, IPO, biomanufacturing, synthetic biology, common stock, Invizyne Technologies, MDB Capital Holdings, Public Ventures, SimplePath, enzymes, biofuels, pharmaceuticals, cannabinoids